Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models.
Blood Purif
; 46(3): 239-245, 2018.
Article
en En
| MEDLINE
| ID: mdl-29972828
ABSTRACT
BACKGROUND/AIMS:
Antibody-mediated rejection (AMR) is related to circulating donor-specific anti-human leukocyte antigen alloantibodies (DSAs). DSAs can be removed by apheresis, for example, double-filtration plasmapheresis (DFPP). However, DFPP removes some clotting factors (fibrinogen and factor XIII [FXIII]).METHODS:
This was a prospective trial including 6 DSA-mediated AMR kidney transplant recipients. Patients received 2 cycles of 3-4 consecutive DFPP sessions followed by 1 injection of rituximab (break of 4-5 days between the 2 cycles). We monitored fibrinogen and FXIII levels before and after each session of DFPP.RESULTS:
Overall, fibrinogen and FXIII levels were significantly decreased after each session, and were significantly reduced between the very first and very last sessions. In addition, we established a model that predicted fibrinogen and FXIII values after each session and after 2 cycles.CONCLUSION:
We established a model in order to predict fibrinogen and FXIII depletion after DFPP sessions; it may help clinicians supplement fibrinogen and/or FXIII when appropriate.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Factor XIII
/
Fibrinógeno
/
Trasplante de Riñón
/
Plasmaféresis
/
Rechazo de Injerto
/
Isoanticuerpos
/
Modelos Biológicos
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Blood Purif
Año:
2018
Tipo del documento:
Article